Financials Scandinavian ChemoTech AB
Equities
CMOTEC B
SE0009242654
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.15 SEK | -1.83% | -4.02% | -20.37% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 81.91 | 164.1 | 60.67 | 38.57 | 38.57 | - |
Enterprise Value (EV) 1 | 81.91 | 164.1 | 60.67 | 43.97 | 32.37 | 38.57 |
P/E ratio | -5.72 x | - | -2.21 x | -1.73 x | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 57.4 x | 3,349 x | - | 15.6 x | 7.71 x | 3.98 x |
EV / Revenue | 57.4 x | 3,349 x | - | 15.6 x | 6.47 x | 3.98 x |
EV / EBITDA | - | -11.5 x | - | -2.5 x | -1.89 x | -2.49 x |
EV / FCF | - | - | - | -2.36 x | - | - |
FCF Yield | - | - | - | -42.3% | - | - |
Price to Book | - | 6.86 x | - | - | - | - |
Nbr of stocks (in thousands) | 6,045 | 9,629 | 12,014 | 17,937 | 17,937 | - |
Reference price 2 | 13.55 | 17.04 | 5.050 | 2.150 | 2.150 | 2.150 |
Announcement Date | 3/8/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | 1.427 | 0.049 | - | 2.822 | 5 | 9.7 |
EBITDA 1 | - | -14.26 | - | -17.56 | -17.1 | -15.5 |
EBIT 1 | - | -17.08 | - | -20.24 | -19.6 | -18 |
Operating Margin | - | -34,851.02% | - | -717.12% | -392% | -185.57% |
Earnings before Tax (EBT) 1 | - | - | - | -21.09 | -19.6 | -18 |
Net income 1 | - | - | -22.75 | -21.09 | -19.6 | -18 |
Net margin | - | - | - | -747.38% | -392% | -185.57% |
EPS 2 | -2.370 | - | -2.280 | -1.560 | - | - |
Free Cash Flow 1 | - | - | - | -18 | - | - |
FCF margin | - | - | - | -529.41% | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/8/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 1.181 | 1.08 | 0.8 | 1 | 1.8 | 1.4 | 1.8 |
EBITDA 1 | - | -5.245 | -3.319 | -4.6 | -4.4 | - | -4.2 | -3.9 |
EBIT 1 | - | -5.978 | -4.026 | -5.2 | -5.1 | - | -4.8 | -4.5 |
Operating Margin | - | -506.18% | -372.78% | -650% | -510% | - | -342.86% | -250% |
Earnings before Tax (EBT) | -5.034 | - | - | - | - | - | - | - |
Net income | -5.034 | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 5/25/23 | 8/15/23 | 10/17/23 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4 | - | - |
Net Cash position 1 | - | - | - | - | 6.2 | - |
Leverage (Debt/EBITDA) | - | - | - | -0.2564 x | - | - |
Free Cash Flow 1 | - | - | - | -18 | - | - |
ROE (net income / shareholders' equity) | - | -107% | - | -169% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | 2.480 | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | 3.33 | - | - | - | - |
Capex / Sales | - | 6,795.92% | - | - | - | - |
Announcement Date | 3/8/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.37% | 3.57M | |
+7.84% | 218B | |
+7.35% | 184B | |
+13.04% | 135B | |
+26.03% | 107B | |
-1.33% | 62.38B | |
+11.80% | 51.37B | |
+4.81% | 50.9B | |
+0.30% | 40.87B | |
+2.78% | 36.28B |
- Stock Market
- Equities
- CMOTEC B Stock
- Financials Scandinavian ChemoTech AB